Autres langues Tango Therapeutics, Inc.

Actions

TNGX

US87583X1090

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 15/05/2024			Varia. 5j.	Varia. 1 janv.
7,8 ^USD	+2,63 %		-1,39 %	-21,21 %

08/05	Tango Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
04/04	Le milliardaire britannique Joe Lewis condamné à une amende de 5 millions de dollars par un juge américain pour délit d'initié	RE

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Tango Therapeutics : Corporate Presentation	08/05
Tango Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights	08/05
British billionaire Joe Lewis fined $5 million by US judge for insider trading	04/04
Multibillionaire Joe Lewis to face US sentencing for insider trading	04/04
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/04
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q4 Revenue $5.4M	18/03
Tango Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights	18/03
Tango Therapeutics, Inc.(NasdaqGM:TNGX) added to S&P Biotechnology Select Industry Index	18/03
Tango Therapeutics to Participate in Upcoming Investor Conferences	06/03
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024	05/03
Tango Therapeutics to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	31/01
British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says	24/01
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/01
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	04/01
Medivir's licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	04/01
Tango Therapeutics Doses First Patient in Phase 1/2 Trial of Cancer Treatment TNG348	03/01
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers	03/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Tango Therapeutics, Inc.

Actions

TNGX

US87583X1090

Autres langues

Filtres